Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

An Unfortunate Step for MannKind As Its Stock Plunges Over Partnership Uncertainty

This article was originally published in The Pink Sheet Daily

Executive Summary

Some analysts see more market opportunity for the company's inhaled Phase I GLP-1 drug than the Afresa insulin inhaler.
Advertisement

Related Content

New MannKind Data Appear Positive, But Doubts Persist About Afrezza's Viability
New MannKind Data Appear Positive, But Doubts Persist About Afrezza's Viability
MannKind CEO Is Optimistic About Near-Term Approval of Afrezza
MannKind CEO Is Optimistic About Near-Term Approval of Afrezza
MannKind CEO Is Optimistic About Near-Term Approval Of Afrezza
MannKind CEO Is Optimistic About Near-Term Approval Of Afrezza
Despite Exubera Scare, Mannkind Marches On
Nektar Seeking New Partner For Exubera As Pfizer Returns Rights
Nektar Seeking New Partner For Exubera As Pfizer Returns Rights

Topics

Advertisement
UsernamePublicRestriction

Register

PS068698

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel